The purpose of this randomized, double-blind, double-dummy study is to evaluate efficacy of remibrutinib in comparison to dupilumab in treating adult participants who have Chronic Spontaneous Urticaria (CSU). The study will compare the efficacy of remibrutinib with dupilumab to see which one works better in helping people with CSU who haven't found relief with use of second-generation antihistamin...